Weinberger 2010.

Methods	SELEGILINE Randomized controlled trial Setting: clinics, USA Recruitment: community volunteers
Participants	101 smokers (excludes 2 taking no medication), 50% F, av. age 47, av. CPD 22, 28% had history of MDD
Interventions	1. Selegiline 10 mg/day for 9 weeks (5 mg/day in w1 & w9) 2. Placebo Both arms; brief weekly counselling
Outcomes	Abstinence at 6m (7‐day PP) Validation: CO & cotinine
Notes	Previously included as Weinberger 2009 based on unpublished data. Minor change to data based on published report in 2013 update. Funding: National Institute of Drug Abuse, Veteran's Administration, Women's Health Research at Yale, NIH, University of Toronto.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization method not described.
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) All outcomes	Low risk	"Both participants and research staff were blinded to study medication assignment," assessments of staff and participants suggest blinding was adequate
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	27.5% selegiline, 42% placebo lost at 6 months. Including all participants is less conservative.